PAST TOP PICK

(Past Top Pick on April 13, 2017, Up 24%) The largest private equity company in the world. A catalyst are the changing tax laws in the States. They're grown aggressively. They have $100 billion of cash to buy new deals. It's a good time to exit parts of their operation. Many US pension plans hire Blackstone to handle their private equity.

PAST TOP PICK

(Past Top Pick on April 13, 2017, Up 37%) Have a great wealth franchise, investment bank, retail franchise and global operations. Also, banking regulations are changing in their favour. Warren Buffett owns 6%. The wind's at their back.

BUY

An inexpensive stock. MS has a strong wealth management business and huge retail brokerage business that have really helped them. However, MS doesn't really have a retail banking franchise, so they lose that cushion in times of volatility. That said, this is one of the top investment banks around. They've enjoyed good numbers. You can do well with this. Good stock, but he prefers the more retail-oriented BAC.

TOP PICK

Trading at 9x earnings and paying a 3.1% dividend. The success of their large Aetna purchase (which still needs approval) will depend on how well CVS integrates it, which is risky. CVS is about integration: long-term care, pharmacy and home fusion. This integration can propel higher margins. (Analysts' price target: $86.81)

TOP PICK

It's like Dollarama. It's doing very well with same-store sales up 4% in their last report. However, they bought Family Dollar and undestimated their issues: lower margins, weakly trained staff, poorer inventory systems. So, this margin has some problems, which has pressured the stock. But this present a buying opportunity. (Analysts' price target: $102.71)

TOP PICK

Two divisions in real estate: property magnament and brands like California Closets and Paul Davis. They manage condos, mostly in gated communities in the U.S. There's little capex, but a lot of free cash flow. They've done well with acquisitions and enjoyed earnings growth with good EBIT margins. (Analysts' price target: $95.22)